Lv1
50 积分 2024-11-21 加入
Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer
9天前
已完结
Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors
9天前
已完结
Current Status of Human Papillomavirus–Targeted Therapies Development in Head and Neck Cancer
10天前
已完结
Pembrolizumab in the first-line treatment of advanced head and neck cancer
10天前
已完结
A Review of Immunotherapy for Head and Neck Cancer
10天前
已完结
Immunotherapy for Head and Neck Cancer
10天前
已完结
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer
10天前
已关闭
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial
10天前
已完结
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial
14天前
已完结
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial
22天前
已完结
皖公网安备34019202002308
